Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Min Geol Lee, Yu Huei Huang, Joo Heung Lee, Seung Chul Lee, Tae Gyun Kim, Derrick Chen Wee Aw, Weibin Bao, Cathleen Michelle A. Dee, Adriana Guana, Tsen Fang Tsai

Research output: Contribution to journalArticle

Abstract

The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double-blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.

Original languageEnglish
Pages (from-to)752-758
Number of pages7
JournalJournal of Dermatology
Volume46
Issue number9
DOIs
Publication statusPublished - 2019 Sep 1

Fingerprint

Psoriasis
Skin
Safety
Ustekinumab
secukinumab
Injections

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Lee, Min Geol ; Huang, Yu Huei ; Lee, Joo Heung ; Lee, Seung Chul ; Kim, Tae Gyun ; Aw, Derrick Chen Wee ; Bao, Weibin ; Dee, Cathleen Michelle A. ; Guana, Adriana ; Tsai, Tsen Fang. / Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab : Subgroup analysis from the CLEAR study. In: Journal of Dermatology. 2019 ; Vol. 46, No. 9. pp. 752-758.
@article{f22b73512e394f459047c7998bf5353d,
title = "Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study",
abstract = "The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double-blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90{\%} or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3{\%} vs 35.9{\%}, P = 0.0010) and at week 52 (60.9{\%} vs 33.3{\%}, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5{\%} vs 10.3{\%}, P = 0.0029) and at week 52 (30.4{\%} vs 12.8{\%}, P = 0.0704). The median time to achieve 50{\%} improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7{\%} and 84.6{\%} of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.",
author = "Lee, {Min Geol} and Huang, {Yu Huei} and Lee, {Joo Heung} and Lee, {Seung Chul} and Kim, {Tae Gyun} and Aw, {Derrick Chen Wee} and Weibin Bao and Dee, {Cathleen Michelle A.} and Adriana Guana and Tsai, {Tsen Fang}",
year = "2019",
month = "9",
day = "1",
doi = "10.1111/1346-8138.15004",
language = "English",
volume = "46",
pages = "752--758",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "9",

}

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab : Subgroup analysis from the CLEAR study. / Lee, Min Geol; Huang, Yu Huei; Lee, Joo Heung; Lee, Seung Chul; Kim, Tae Gyun; Aw, Derrick Chen Wee; Bao, Weibin; Dee, Cathleen Michelle A.; Guana, Adriana; Tsai, Tsen Fang.

In: Journal of Dermatology, Vol. 46, No. 9, 01.09.2019, p. 752-758.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab

T2 - Subgroup analysis from the CLEAR study

AU - Lee, Min Geol

AU - Huang, Yu Huei

AU - Lee, Joo Heung

AU - Lee, Seung Chul

AU - Kim, Tae Gyun

AU - Aw, Derrick Chen Wee

AU - Bao, Weibin

AU - Dee, Cathleen Michelle A.

AU - Guana, Adriana

AU - Tsai, Tsen Fang

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double-blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.

AB - The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double-blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.

UR - http://www.scopus.com/inward/record.url?scp=85069859170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069859170&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.15004

DO - 10.1111/1346-8138.15004

M3 - Article

C2 - 31342560

AN - SCOPUS:85069859170

VL - 46

SP - 752

EP - 758

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 9

ER -